Loomis, Sayles & Company
BHVN

Loomis, Sayles & Company’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Loomis, Sayles & Company’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-361,363
Closed -$18.6M – 818
2019
Q1 		$18.6M Buy
+361,363
New +$15.6M 0.04% 219

Other funds holding BHVN

Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Loomis, Sayles & Company's BHVN Position: Q2 2019 in Review

Loomis, Sayles & Company sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2019, closing a stake of 361,363 shares — an estimated $18.6M sold.

Loomis, Sayles & Company first reported a position in BHVN in Q1 2019 and held it in 1 quarter. The position peaked at $18.6M in Q1 2019. 197 funds tracked by Wall St. Rank hold BHVN as of Q2 2019.

  • Loomis, Sayles & Company reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2019 after selling out during the quarter.
  • Loomis, Sayles & Company sold 361,363 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2019, an estimated $18.6M.
  • Loomis, Sayles & Company first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 1 quarter.
  • Loomis, Sayles & Company's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $18.6M in Q1 2019.
  • 197 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2019.

Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.